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Breast cancerThe ErbB3 receptor is an important regulator of cell growth and carcinogenesis. Among breast cancer patients, up
to 50–70% have ErbB3 overexpression and 20–30% show overexpressed or ampliﬁed ErbB2. ErbB3 has also been
implicated in the development of resistance to several drugs used against cancers driven by ErbB1 or ErbB2. One
of the main challenges in ErbB-targeting therapy is to inactivate signaling mediated by ErbB2–ErbB3 oncogenic
receptor complexes. We analyzed the regulatory role of ﬂotillins on ErbB3 levels and ErbB2–ErbB3 complexes
in SKBR3, MCF7 and MDA-MB-134-VI human breast cancer cells. Recently, we described a mechanism for inter-
fering with ErbB2 signaling in breast cancer and demonstrated a molecular complex of ﬂotillin scaffolding pro-
teins with ErbB2 and Hsp90. In the present study, ﬂotillins were found to be in a molecular complex with
ErbB3, even in cells without the presence of ErbB2 or other ErbB receptors. Depletion of either ﬂotillin-1 or
ﬂotillin-2 resulted in downregulation of ErbB3 and a selective reduction of ErbB2–ErbB3 receptor complexes.
Moreover, ﬂotillin-2 depletion resulted in reduced activation of Akt and MAPK signaling cascades, and as a
functional consequence of ﬂotillin depletion, breast cancer cells showed an impaired cell migration.
Altogether, we provide data demonstrating a novel and functional role of ﬂotillins in the regulation of ErbB
protein levels and stabilization of ErbB2–ErbB3 receptor complexes. Thus, ﬂotillins are crucial regulators for
oncogenic ErbB function and potential targets for cancer treatment.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
The four members of the human epidermal growth factor receptor
family (ErbB1–4) are essential mediators of cell proliferation and differ-
entiation in embryonic and adult tissues [23,54]. Activation of ErbB-
mediated signaling is strongly associated with tumorigenesis [24].
ErbB receptors mediate signaling mainly through the RAS/RAF/MAPK
pathway, which regulates cell proliferation, and the PI3K/Akt pathway,
which promotes cell survival [54,55].
ErbB3 has been observed to preferentially heterodimerize with
ErbB2 in several cancers. This dimer is known to trigger proliferation,
survival and transformation of human breast cells more potently than
other ErbB receptor dimers [22], probably by its ability to recruit a
large set of signaling molecules [20]. Increased ErbB3 expression is
often found in ErbB2 positive cancer types, and ErbB2 expression is cor-
related with poor prognosis for cancer patients [8,22,26,54].
Several ErbB targeted therapies have been developed and are in clin-
ical use [24,37]. However, many cancer patients do not respond or de-
velop drug-resistant cancers after treatment with ErbB1 or ErbB2y, Institute for Cancer Research,targeting agents [39]. In some cases, this resistance is linked to ErbB3
mediated compensatory mechanisms that allow cancer cells to restore
PI3K/Akt growth promoted signaling [16,17,19,38]. ErbB3 downregula-
tion has been shown to prevent formation and growth of mammary tu-
mors in transgenic mice [11] and to decrease Akt phosphorylation in
SKBR3 breast cancer cells [22]. Thus, efﬁcient inhibition of ErbB2–
ErbB3 complex formation might help in targeting tumors in patients
with ErbB-mediated PI3K/Akt signaling.
In a recent paper from our lab, we demonstrated a positive correla-
tion between lipid raft-associated ﬂotillins and ErbB2 in breast cancer
cells and tissue [33]. Flotillin-1 and ﬂotillin-2 scaffolding proteins were
found to be in amolecular complexwith ErbB2 andHsp90, contributing
to the stabilization of ErbB2 at the cell surface of SKBR3 cells [33].
Flotillins are highly conserved proteins that are ubiquitously expressed
and associated with cellularmembranes through palmitoylation and/or
myristoylation [30]. The expression pattern of ﬂotillins and their subcel-
lular localization is cell type speciﬁc. However, ﬂotillins are not only
mainly localized at the plasma membrane, but also localized at
endosomal and lysosomal compartments [12,14]. Flotillins are not
only involved in various cellular processes including endocytosis, reor-
ganization of the actin cytoskeleton and receptormediated signal trans-
duction, including regulation of receptor tyrosine kinases [25,31,49], but
also implicated in carcinogenesis of several human cancers [6,28,51].
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tion of ErbB3 and its heterodimeric signaling complex with ErbB2 in
human breast cancer cells. We demonstrate that ﬂotillins are in com-
plex with ErbB3 that can form independent of ErbB2 or other ErbB re-
ceptors. Flotillin depletion induces downregulation of ErbB3 protein
levels in the breast cancer cell lines we tested. Importantly, ﬂotillin
knockdown results in a reduction of ErbB2–ErbB3 signaling complexes
that play a critical role in human breast cancer signaling. Moreover,
ﬂotillin knockdown impairs breast cancer cell migration, and ﬂotillin-2
knockdown reduces Akt and MAPK phosphorylation. In summary, our
data reveal an important role for ﬂotillins in the regulation of ErbB2
and ErbB3 protein levels and in the stabilization and maintenance of
ErbB2–ErbB3 receptor complexes and downstream signaling pathways.
2. Materials and methods
2.1. Antibodies
Antibodies used for immunoblotting: mouse anti-ﬂotillin-1 and -2
(BD-Bioscience, NJ), sheep anti-ErbB1 (Fitzgerald Industries Interna-
tional, MA), rabbit anti-ErbB2 (29D8, Cell Signaling, Danvers, MA),
mouse anti-ErbB2 (Ab-17, Thermo Fisher Scientiﬁc), rabbit anti-ErbB3
(Ab-1328, Sigma Aldrich, MO), rabbit anti-ErbB4 (1200-1, Epitomics,
CA), mouse anti-GAPDH (Ab-9484, Abcam, Cambridge), mouse anti-
GFP (Roche Diagnostics, IN), rabbit anti-Erk1/2 (9102, Cell Signaling,
MA), mouse anti-phospho-Erk1/2 (Thr202/Tyr204) (9106, Cell Signal-
ing, MA), rabbit anti-Akt (9272, Cell Signaling, MA), and rabbit anti-
phospho Akt (Ser473) (4058, Cell Signaling, MA).
Antibodies used for protein immunoprecipitation analysis: mouse
anti-ErbB2 (Ab-17, Thermo Fisher Scientiﬁc), mouse anti-ﬂotillin-1
(C-7, Santa Cruz Biotechnologies, CA), mouse anti-ﬂotillin-2 (B-6,
Santa Cruz Biotechnologies, CA) and control mouse IgG (Santa Cruz
Biotechnologies, CA). Primary antibodies used for PLA-assays and ﬂuo-
rescence microscopy: rabbit anti-ErbB2 (29D8, Cell Signaling, MA),
mouse anti-ErbB3 (2F12, Millipore, MA), mouse anti-ﬂotillin-1 (C-7,
Santa Cruz Biotechnologies, CA), and mouse anti-ﬂotillin-2 (B-6, Santa
Cruz Biotechnologies, CA).
2.2. Cell culture
Human breast carcinoma SKBR3 cells (ATCC: HTB-30) were grown
in DMEM (Invitrogen Life Technologies, CA) and MCF7 cells (ATCC:
HTB-22) in RPMI (Invitrogen Life Technologies, CA) both supplemented
with 10% v/v fetal bovine serum (SigmaAldrich,MO), 100 U/mL penicil-
lin and 100 U/mL streptomycin (Invitrogen Life Technologies, CA) for
complete medium conditions. Both cell lines were grown at 5% CO2
and seeded 24 h prior to experiment. For RNAi mediated knockdown,
MCF7 and SKBR3 cells were seeded without serum and antibiotics
in six-well plates with 2 × 105 cells/well and 3 × 105 cells/well for
MDA-MB-134-VI cells. For plasmid transfection, SKBR3 cellswere seeded
in complete growth medium in a six-well plate with 3 × 105 cells/well.
MDA-MB-134-VI human breast carcinoma (ATCC: HTB-22, Teddington,
Middlesex) were grown in complete Leibovitz's L-15 growth medium
(Invitrogen Life Technologies, CA) supplemented with 20% v/v FBS
(Sigma Aldrich, MO) and grown at 37 °C in 100% air.
2.3. Plasmid and siRNA transfection
For siRNA transfection, ON-TARGETplus single and/or SMARTpool of
four siRNA oligos were used to reduce unspeciﬁc off-target effects. Con-
trol non-targeting and ErbB2, ErbB3, ﬂotillin-1 and ﬂotillin-2 targeting
oligos were purchased from Thermo Fisher Scientiﬁc (Waltham, MA).
Cells were transfectedwith siRNA using Lipofectamine RNAiMAX trans-
fection reagent (Invitrogen Life Technologies, CA) according to theman-
ufacturer's protocol. SKBR3 andMCF7 cellswere transfectedwith 25 nM
siRNA oligo and 50 nM was used for MDA-MB-134-VI cells, targetingeither ErbB2 (UGGAAGAGAUCACAGGUUA, GAGACCCGCUGAACAA
UAC, GGAGGAA-UGCCGAGUACUG, GCUCAUCGCUCACAACCAA) or
ErbB3 (GCGAUGCUGAGAACCAAUA, AGA-UUGUGCUCACGGGACA,
GCAGUGGAUUC-GAGAAGUG, UCGUCAUGUUGAACUAUAA). SiRNA
oligos targeting ﬂotillin-1 and ﬂotillin-2 were used as described earlier
[32]. The cells were transfected for 6 h and subsequently grown in com-
plete growth medium for 3 additional days prior to experiments.
For plasmid transfection, cells were seeded in complete growth me-
dium 1 day prior to experiment and transfected with ﬂotillin-1-GFP,
ﬂotillin-2-GFP, ErbB2-GFP or ErbB3-CFP for 24 h by using FuGENE6
transfection reagent (Promega, WI) as described by the manufacturer.
The plasmid expressing ﬂotillin-1 was a kind gift from Dr. Stephen M.
Robbins (University of Calgary, Canada), ﬂotillin-2 was provided by
Dr. Caludia A.O. Stuermer (University of Konstanz, Germany) and
GFP-ErbB2 was from Dr. Bo van Deurs (University of Copenhagen,
Denmark). The ErbB3-CFP plasmid [47] was kindly provided by Dr.
IchiroMaruyama (Okinawa Institute of Science and Technology, Japan).2.4. Immunoﬂuorescence and confocal microscopy
Cells were grown on glass cover slips and ﬁxed in 4% methanol free
paraformaldehyde (Polysciences) for 15 min and permeabilized with
0.1% Triton X-100 in PBS for 2 min, before blocking in 10% FCS for 1 h
at RT. The samples were subsequently immunostained with primary
antibodies in 10% FCS for 1 h at RT, followed by 45 min incuba-
tion with ﬂuorophore-conjugated secondary antibodies (Jackson
ImmunoResearch Laboratories) in 10% FCS. The samples were mounted
in ProLong Gold with DAPI (Molecular Probes, Invitrogen Life Technolo-
gies, CA) and images were acquired using confocal laser scanning mi-
croscope (LSM) 710 or 780 (Carl Zeiss). LSM Image Browser software
(Carl Zeiss) or ImageJ software (National Institutes of Health) was
used for further image analysis and quantiﬁcation of signal intensities.2.5. Duolink — in situ proximity ligation assay
In situ proximity ligation assay kit Duolink-II (Olink Bioscience) was
used to analyze and quantify protein interactions. The cells were
washed in PBS, ﬁxed in 10% formalin (Sigma) for 15 min, and perme-
abilized with 0.1% Triton X-100 in PBS for 2 min. Primary antibodies
raised against ErbB2 and ErbB3 were used and the PLA reactions were
performed as described in the manufacturer's instructions. All reagents
used for the PLA assay were from Olink Bioscience. The samples were
mounted with Duolink Mounting Medium (Olink Bioscience) and im-
ages were acquired by LSM-710 or LSM-780 confocal microscope (Carl
Zeiss) and analyzed with ImageJ software (National Institutes of
Health). For the negative controls, only one antibody was used as a
probe. Mitotic cells and cells from dense ﬁelds were excluded from
the analysis.2.6. Western blotting
Cell lysates were prepared as described previously by our lab
[33]. Proteins were separated by SDS-PAGE on a 4–20% gradient gel
(Protean-TGX, Bio-Rad) and blotted onto a PVDF membrane
(Immobilon-FL, Millipore, MA). The membrane was blocked in 5% w/v
BSA (Sigma) in PBS with 0.1% Tween-20 (PBS-T) before incubating
with the primary antibody overnight at 4 °C. After washing with PBS-
T, IRDye infrared linked secondary antibodies (LI-COR Biosciences)
were used according to themanufacturer's manual. The bandswere de-
tected by Odyssey Infrared Imaging System (LI-COR Biosciences) and
quantiﬁed using Quantity One® software (Bio-Rad Laboratories). Levels
of GAPDHwere used as internal loading controls and data were further
correlated to those of the control treatments.
1989N. Asp et al. / Biochimica et Biophysica Acta 1843 (2014) 1987–19962.7. Immunoprecipitation
Cell lysates were prepared as described in the previous session. 1 μg
of rabbit anti-ErbB2, anti-ﬂotillin-1, anti-ﬂotillin-2 or equivalent
concentration of control mouse IgG, was preincubated with Protein
G-sepharose beads (Amersham Biosciences) for 2 h at 4 °C in PBS.
Equivalent amounts of cell lysates from each sample were immuno-
precipitated overnight at 4 °C with prebound antibody of interest to
the beads. Immunocomplexes were washed with 0.35% Triton X-100
in PBS, separated by SDS-PAGE under reducing conditions, blotted
onto a PVDFmembrane and processed as described in the previous sec-
tion. GFP-fusion proteins were immunoprecipitated by using the GFP-
Trap® A beads (Chromotek) according to the manufacturer's protocol.
2.8. Wound healing assay
MCF7 cells were seeded on Glass Bottom Dishes (MatTek Corpora-
tion) and transfected with non-targeting control, ﬂotillin-1 or ﬂotillin-
2 siRNA and incubated for 3 days. By using a sterile 10 μL pipette tip, a
wound was made in the conﬂuent monolayer, and cells were washed
and subsequently observed with a BioStation IM Live Cell Recorder
(Nikon Instruments Inc.). Image acquisition was done every 10 min
over a period of 7 h. In the case of geldanamycin (GA) treatment, cells
were pre-incubated with 3 μMGA and treatment was continued during
image acquisition. Images were analyzed with ImageJ software and by
Chemotaxis and Migration Tool (ibidi GmbH) and only non-dividing
and vital single cells have been taken in account. Directionality was cal-
culated by dividing the Euclidean distance by the accumulated distance
of the cell trajectories.
2.9. Statistics
Student's t-test or Mann–Whitney rank sum test was used to calcu-
late the P-value for all experiments. A P-value of 0.05 or less was consid-
ered to be statistically signiﬁcant. A minimum of 3 experiments were
performed and quantiﬁcation of the data was given as mean ± SD. For
Duolink experiments, a minimum of 50 cells were analyzed per condi-
tion and experiment.
3. Results
3.1. Geldanamycin induced degradation of ErbB1–4 in different breast
cancer cell lines
In thepresent study, ErbBprotein expression levelswere analyzed in
the three different human breast cancer cell lines SKBR3, MCF7 and
MDA-MB-134-VI. Detectable levels of all ErbB proteins were found in
SKBR3 and MCF7 cells (Fig. 1A). In comparison to SKBR3 cells, MCF7
had low expression levels of ErbB1 and ErbB2 (Fig. 1A). In MDA-MB-
134-VI cells, only ErbB3 was found at detectable levels (Fig. 1B, Supple-
mentary Fig. S1A), which is in line with previous ﬁndings [7,13].
Heat shock protein 90 (Hsp90) is required for the stabilization and
conformational maturation of a subset of proteins [36,56]. Inhibition of
Hsp90 by geldanamycin (GA) has been shown to induce degradation
of ErbB receptors in different cell lines [10,18,52]. To compare the effect
of ﬂotillin depletion and of geldanamycin treatment of all ErbB recep-
tors in the same cell lines under similar conditions, we ﬁrst analyzed
the sensitivity of endogenous ErbB1–4 receptor levels to GA in SKBR3,
MCF7 and MDA-MB-134-VI cells. Cells were treated with 3 μM GA, or
an equivalent amount of DMSO in the control, for different time points
(0–24 h), and full length ErbB proteins were quantiﬁed. In SKBR3 and
MCF7 cells, ErbB1 was slowly degraded between 8 and 24 h (Fig. 1A)
that is consistent with previous ﬁndings, demonstrated in other cell
lines [1,9,52]. ErbB2 was rapidly degraded in both SKBR3 and MCF7
(Fig. 1A, C–D), as previously reported [10,18,48,52,56]. In contrast to
SKBR3 cells (Fig. 1A, C), degradation of ErbB3 was relatively slow inMCF7 cells (Fig. 1A, D). Interestingly, we also observed degradation of
ErbB3 in MDA-MB-134-VI cells (Fig. 1E) that does not express other
ErbB receptors. In contrast to MCF7 (Fig. 1A, D) and to other cell lines
reported elsewhere [10,48], ErbB4 was rapidly degraded in SKBR3
cells (Fig. 1A, C). Only long term GA treatment (8–24 h) triggered
ErbB4 degradation in MCF7 cells (Fig. 1A, D). These data show that
ErbB receptors exhibit cell line dependent variations in the expression
levels as well as in the dynamics of their GA-induced degradation.
3.2. Co-immunoprecipitation and colocalization of ﬂotillins with ErbB3
Wedemonstrated earlier that depletion of ﬂotillin-1 or ﬂotillin-2 re-
sults in internalization and degradation of ErbB2 in SKBR3 cells [33]. In
order to determinewhether downregulation ofﬂotillins has a similar ef-
fect on other ErbB receptors, immunoprecipitation experiments were
performed to determine whether ﬂotillins are in a complex with
ErbB3. SKBR3 cells were incubated for 24 h after transfection with plas-
mids encoding GFP, ﬂotillin-1-GFP, ﬂotillin-2-GFP or ErbB2-GFP follow-
ed by a 4 h treatment with GA or DMSO in the control. Transfection
efﬁciencies of the plasmids were determined by ﬂuorescent microsco-
py. Samples with at least 60–70% positively transfected cells were
used for further analysis. By co-immunoprecipitation analysis, an inter-
action between ErbB2 and ErbB3 was demonstrated in SKBR3 cells,
reﬂecting the abundance of ErbB2–ErbB3 dimers in SKBR3 (Fig. 2A).
Upon 4 h of GA treatment, ErbB2 and ErbB3 levels were dramatically
reduced, consequently a reduced pulldown of ErbB3 was obtained.
Importantly, co-immunoprecipitation of ErbB3 with ﬂotillin-1 as well
as with ﬂotillin-2 was observed in SKBR3 cells (Fig. 2A, B).
In order to exclude that the interaction of ErbB3 with ﬂotillins is ex-
clusively mediated by ErbB2, the MDA-MB-134-VI cell line, which only
expresses ErbB3, was used for further analysis. Pulldown of endogenous
ﬂotillin-1 (Fig. 2C) or ﬂotillin-2 (Fig. 2D) inMDA-MB-134-VI cells led to
co-immunoprecipitation of ErbB3. Thus, results conducted in SKBR3 and
MDA-MB-134-VI cells indicate that ﬂotillins are interacting not only
with ErbB2 but alsowith ErbB3, and this interaction can be independent
of ErbB2 or other ErbB receptors. To show that endogenous ﬂotillin-1
and -2 are colocalized with ErbB3, we transiently transfected SKBR3
cells with ErbB3-CFP [47]. Cells were ﬁxed and stained for endogenous
ﬂotillin-1/-2 and moderately transfected cells were analyzed by
confocal microscopy (Fig. 2E). Flotillins and ErbB3 show a partial
colocalization at the plasma membrane, as indicated by line plot
proﬁles.
3.3. Flotillin depletion induces ErbB3 receptor downregulation
In order to determine the role of endogenous ﬂotillins on the regula-
tion of ErbB3 protein levels, MCF7, SKBR3 and MDA-MB-134-VI cell
lines were depleted for either ﬂotillin-1 or ﬂotillin-2 (Fig. 3A) by using
siRNA technology and ErbB protein levels were quantiﬁed for all three
cell lines (Fig. 3B–D). 72 h after siRNA transfection, the protein expres-
sion of ﬂotillin-1 or ﬂotillin-2 was reduced by 70–90% and 40–80%,
respectively, in MCF7 cells (Fig. 3A and Supplementary Fig. S1B),
50–95% and 60–90% in SKBR3 cells [33] and 40–80% and 55–80% in
MDA-MB-134-VI cells (Supplementary Fig. S1C). By Western blot anal-
ysis wewere able to show that depletion of ﬂotillins resulted in a signif-
icant reduction of endogenous ErbB2 and ErbB3 protein levels in MCF7
and SKBR3 cells (Fig. 3B–C and Supplementary Table S2). In ﬂotillin de-
pleted MCF7 cells, ErbB2 protein levels were reduced by ~20% and
ErbB3 protein levelswere reduced by ~30–35% (Fig. 3B and Supplemen-
tary Table S2). In SKBR3 cells, ErbB2 protein levels were decreased by
~25% and ErbB3 protein levels were decreased by ~30% upon knock-
down of ﬂotillins (Fig. 3C and Supplementary Table S2).
As ErbB2 is the preferred dimerization partner of ErbB3, we next an-
alyzed the possibility that ﬂotillin induced ErbB3 downregulationmight
be an indirect effect mediated by ErbB2 degradation. Therefore, SKBR3
and MCF7 cells were depleted for ErbB2 or ErbB3 and the levels of all
Fig. 1. ErbB receptor expression levels and their dependency onHsp90 vary between different breast cancer cell lines. (A) SKBR3 andMCF7 cellswere treatedwith 3 μMGAor DMSO in the
control and lysed at indicated time points. Cell lysates from each sample were resolved by SDS-PAGE and immunoblotted using antibodies (see Section 2.1) to detect full length ErbB1,
ErbB2, ErbB3 or ErbB4 receptors and GAPDH as a loading control. Arrow indicates the speciﬁc band of the corresponding full length ErbB1 receptors. (B) ErbB protein levels detected in
MDA-MB-134-VI and SKBR3 cells. Western blot analysis did show that MDA-MB-134-VI cells exclusively express ErbB3 receptor. Quantiﬁcation of ErbB receptor levels in control and
GA treated SKBR3 (C, n= 3), MCF7 (D, n= 3) andMDA-MB-134-VI (E, n = 4–5) cells. ErbB1 (black), ErbB2 (red), ErbB3 (green) and ErbB4 (yellow) protein expression levels were nor-
malized to GAPDH levels. Mean ± SD.
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tion resulted in decreased ErbB3 (~50%) and ErbB4 (~80%) protein
levels and ErbB3 depletion resulted in decreased ErbB2 (~20%) protein
levels (Fig. 4A). This was also conﬁrmed by confocal microscopy analy-
sis showing a clear decrease in membrane associated ErbB3 intensity
upon depletion of ErbB2 in SKBR3 cells (Fig. 4B). However, ErbB3 deple-
tion did not affect ErbB2 staining in the same cell line (Fig. 4B). InMCF7,
ErbB2 or ErbB3 depletion did not affect the protein levels for any of the
other ErbB receptors (Fig. 4C). These data show that ErbB3 levels seems
to be less dependent on ErbB2 in MCF7 compared to SKBR3 cells, sug-
gesting that ﬂotillin mediated downregulation of ErbB3 in MCF7 cells
seems to be rather independent of ErbB2. To further investigate wheth-
er ﬂotillins regulate or stabilize ErbB3 levels independent of ErbB2 or
other ErbB receptors, MDA-MB-134-VI breast cancer cells were deplet-
ed for ﬂotillins and ErbB3 protein levels were analyzed by SDS-PAGE.
Endogenous ErbB3 protein level was signiﬁcantly downregulatedupon knockdown of ﬂotillin-1 or ﬂotillin-2 by ~13% and ~35%, respec-
tively (Fig. 3D). In summary, these data show that depletion of ﬂotillins
triggers ErbB3 receptor degradation to different extent in different
human breast cancer cell lines.3.4. Flotillin depletion reduces the amount of ErbB2–ErbB3 dimers
Next, we investigated the role of ﬂotillins in the stabilization or
maintenance of ErbB2–ErbB3 receptor complexes. The interaction be-
tween ErbB2 and ErbB3 receptors was analyzed after knockdown of
ﬂotillins in SKBR3 and MCF7 cells. This was achieved by using the
established in situ proximity ligation assay (PLA) (Duolink-II kit, Olink
Bioscience). Brieﬂy, this method is based on antibody detection of pro-
tein–protein interactions occurring within 40 nm, which are visualized
as distinct ﬂuorescent dots by ﬂuorescence microscopy [41].
Fig. 2. ErbB3 receptor interacts and colocalizeswith ﬂotillins. SKBR3 cells were transfectedwith ﬂotillin-1-GFP, ﬂotillin-2-GFP or ErbB2-GFP for 24 h. Immunoprecipitationwas performed
by using GFP trap beads and immunoblotting against ErbB3 or GFP was carried out to verify GFP immunoprecipitation efﬁciency. (A) Immunoprecipitation of GFP tagged ﬂotillin-1,
ﬂotillin-2 or ErbB2 by GFP-TRAP resulted in co-immunoprecipitation of ErbB3. Reduced pulldown of ErbB3 was obtained upon 4 h GA treatment (3 μM). (B) Quantiﬁcation of GFP-
TRAP experiments, described in (A). The band intensity of precipitated complexes of 3–5 independent experiments has been calculated and normalized to the GFP control. Compared
to the GFP control, ErbB3 bands were increased to 200% in GFP-ﬂotillin-1/-2 and the GFP-ErbB2 was increased to 500% (** P b 0.01, *** P b 0.001). Co-immunoprecipitation of ErbB3
with endogenous ﬂotillin-1 (C) or ﬂotillin-2 (D) in MDA-MB-134-VI cells. (E) Colocalization of ﬂotillins with ErbB3. SKBR3 cells were transfected with CFP-ErbB3, ﬁxed in MeOH and
stained for endogenous ﬂotillin-1 and ﬂotillin-2 (mouse antibodies, as speciﬁed in Section 2.1). Flotillin-1 and -2 show a partial colocalization with ErbB3 at the plasma membrane, as
speciﬁed in the line plot proﬁle. Scale bars, 5 μm. Antibodies used for immunoblotting and immunoprecipitation, Materials and methods, Section 2.1.
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indicating the heterodimerization of these receptors in SKBR3 and
MCF7 cells (Fig. 5A–B). This interaction was reduced upon 2 h GA
treatment by ~40% in SKBR3 cells (P b 0.001, Fig. 5A) and in MCF7
cells (P= 0.029, Fig. 5B). Importantly, the association between ErbB2
and ErbB3 was also reduced after ﬂotillin-1 (~50%, P b 0.001) or
ﬂotillin-2 (~44%, P = 0.014) knockdown in SKBR3 cells (Fig. 5A)
and in MCF7 cells (ﬂotillin-1, ~40%, P = 0.008 and ﬂotillin-2, ~55%,
P = 0.029) (Fig. 5B). The reduced amount of ErbB2–ErbB3 complexes
was conﬁrmed by immunoprecipitation of endogenous ErbB2 in
ﬂotillin-1 or ﬂotillin-2 depleted SKBR3 cells. Immunoprecipitation of
ErbB2 resulted in a pulldown of ErbB3 (Fig. 5C and Supplementary
Fig. S3). ErbB2–ErbB3 complexes were signiﬁcantly reduced upon GAtreatment by ~60% (P = 0.029), compared to DMSO treated control
cells (Fig. 5C). Importantly, ﬂotillin-1 depletion resulted in a ~30%
(P = 0.029) reduction of ErbB2–ErbB3 interaction and a ~40%
(P = 0.029) reduction after ﬂotillin-2 knockdown (Fig. 5C). In order
to exclude that reduced ErbB levels are entirely responsible for reduced
ErbB2–ErbB3 association upon ﬂotillin knockdown, we performed
quantitative analysis of several independent co-immunoprecipitation
experiments (n = 3–4) and normalized the precipitated complexes to
the input protein levels that have been corrected for GAPDH loading.
The results were ﬁnally presented as % of control condition (Fig. 5D). In-
dependent of the reduced ErbB2 and ErbB3 levels, we obtained a signif-
icant decrease (15–20%) in ErbB2–ErbB3 association. Brieﬂy, these data
suggest that ﬂotillin depletion affects the stabilization of ErbB2–ErbB3
Fig. 3. ErbB2 and ErbB3 receptor downregulation upon ﬂotillin depletion. (A) Representative Western blots of ErbB2, ErbB3 and ﬂotillin-1/-2 in control and ﬂotillin depleted MCF7 cells.
GAPDH was used as a loading control. Depletion of ﬂotillins resulted in a signiﬁcant reduction of ErbB2 and ErbB3 protein levels in MCF7 (B, n = 5) and SKBR3 (C, n = 3–7). ErbB3 was
signiﬁcantly downregulated upon depletion of ﬂotillins in MDA-MB-134-VI cells (D, n = 4). Mean + SD. (* P b 0.05, ** P b 0.01, *** P b 0.001).
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receptor dimerization, in different human breast cancer cell lines.
3.5. Flotillin-2 depletion results in reduced Akt and MAPK phosphorylation
levels
After demonstrating that depletion of ﬂotillins results in reduced
ErbB2 and ErbB3 protein levels and disruption of ErbB2–ErbB3 hetero-
dimers, we investigated the effects of ﬂotillin depletion on ErbB trig-
gered signaling pathways. The two major signaling pathways that are
activated by ErbB2–ErbB3 dimers are the RAS/RAF/MAPK pathway
and the PI3K/Akt pathway that regulate cell proliferation and survival
[54,55]. The levels of phosphorylated and total Akt or MAPK were mea-
sured after knockdown of ﬂotillin-1 or ﬂotillin-2 inMCF7 cells (Fig. 6A).
The depletion of ﬂotillin-2 led to a signiﬁcant reduction in the levels
of p-AktSer473 and p-Erk1/2Thr202/Tyr204 by ~30% (P= 0.029) and ~40%
(P= 0.029), respectively (Fig. 6B and C). Flotillin-1 depletion did not af-
fect Akt and MAPK phosphorylation (Fig. 6B and C). The reduced phos-
phorylation of Akt in MCF7 cells upon knockdown of ﬂotillin-2, but not
after ﬂotillin-1 depletion, is in agreementwith our previously published
data obtained in SKBR3 cells [33]. As shown in different cell lines, only
ﬂotillin-2 seems to have a speciﬁc role in the regulation of signaling cas-
cades downstream of ErbB in human breast cancer cells.
3.6. Flotillin depletion affects breast cancer cell migration
Next, we investigated the functional role of ﬂotillins and ﬂotillin-
induced ErbB receptor downregulation and performed cell migration
assays in MCF7 cells. MCF7 were depleted for ﬂotillins or treated with
GA, and wound healing assays of conﬂuent cell layers were performed.
First, we analyzed cell velocity and directionality after GA treatment and
no signiﬁcant changes were observed (Fig. 6D). Next, we measured cell
velocity after knockdown of ﬂotillins and a signiﬁcant reduction wasobtained upon depletion of ﬂotillin-1 or ﬂotillin-2 by ~13% (P b 0.001)
and ~22% (P = 0.012), respectively (Fig. 7, gray bars). Moreover, the
cell directionality of ﬂotillin depleted MCF7 cells was also analyzed
and a signiﬁcant reduction was observed upon knockdown of ﬂotillin-
2 by ~13% (P= 0.008) and a modest but not signiﬁcant reduction was
measured after knockdown of ﬂotillin-1 (~5%, P = 0.133) (Fig. 7).
Double knockdown of ﬂotillin-1 and ﬂotillin-2 resulted in a signiﬁcant
reduction in cell velocity (~23%, P = 0.006) and cell directionality
(~12%, P= 0.007) and did not show any additional effect on cell migra-
tion compared to single knockdown cells. Thus, our results demonstrate
that ﬂotillin scaffolding proteins seem to have a speciﬁc role in breast
cancer cell migration that is independent of ErbB levels as GA-induced
ErbB receptor downregulation did not affect MCF7 cell migration.
4. Discussion
In this study we have investigated the three human breast cancer
cell lines SKBR3, MCF7 and MDA-MB-134-VI cells that all originate
from a luminal breast cancer subtype but exhibit different protein ex-
pression proﬁles [13,34]. ErbB3 is the only expressed ErbB protein in
MDA-MB-134-VI cells [7,13], while all ErbB proteins are expressed in
SKBR3 andMCF7 cells with different expression levels of the various re-
ceptors. Variations in ErbB expression levels might reﬂect the propor-
tion of receptor homo- and/or heterodimers that are formed in SKBR3
and MCF7 cell lines, and that may in turn trigger different signaling
pathways. In the context of ErbB targeted cancer therapy, it is important
to know the individual ErbB expression levels in the target tissue, in
order to efﬁciently target the tumor and to avoid development of resis-
tance after treatment.
Flotillins seem to have a speciﬁc and regulatory role on ErbB recep-
tors in different breast cancer cell lines. It has been shown by others
that ﬂotillin-depletion interferes with EGFR clustering [2] and EGFR
phosphorylation [43] and affects downstream signaling cascades.
Fig. 4. The effect of ErbB2 or ErbB3 receptor depletion on the protein levels of other ErbB receptors. RepresentativeWestern blots of full length ErbB proteins in SKBR3 andMCF7 cells upon
ErbB2 or ErbB3 knockdown. (A) In SKBR3 cells, knockdown of ErbB2 resulted in reduced protein levels of ErbB3 (~50%) and ErbB4 (~80%), and knockdown of ErbB3 resulted in reduced
ErbB2 (~20%) protein levels. No changes were observed in ErbB1 levels upon ErbB2 or ErbB3 depletion. (B) Representative confocal images with ErbB2 and ErbB3 cellular localization in
SKBR3 cells transfected with control, ErbB2 or ErbB3 siRNA. ErbB2 depletion resulted in a reduction of membrane associated ErbB3 receptors. Scale bars, 10 μm. (C) In MCF7 cells, no sig-
niﬁcant changes were observed in ErbB protein levels upon knockdown of ErbB2 or ErbB3 receptors. A and C: Arrows indicate the corresponding band of the full length ErbB1 receptor.
Antibodies used for immunoblotting or immunoﬂuorescence are speciﬁed in Materials and methods, Section 2.1.
1993N. Asp et al. / Biochimica et Biophysica Acta 1843 (2014) 1987–1996Beside the reported effects on EGFR, our data demonstrate a ﬂotillin-
mediated stabilization of ErbB2 and ErbB3 protein levels in different
human breast cancer cell lines. Since ErbB3 is preferentially dimerizing
with ErbB2 [22] one cannot exclude the possibility that ﬂotillin-induced
ErbB3 degradation in SKBR3 cells might be indirectly mediated through
ErbB2. However, in MCF7 cells the interaction between ﬂotillins and
ErbB3 seems to be rather independent of ErbB2, as ErbB3 levels were
not affected upon ErbB2 knockdown.
Importantly, we demonstrate in MDA-MB-134-VI cells that ﬂotillin
knockdownmediates ErbB3 degradation independent of other ErbB re-
ceptors, as this cell line only expresses ErbB3 [7,13]. Zhu et al. [57] re-
ported recently a positive correlation between ﬂotillin-2 and ErbB2
levels in gastric cancer, a ﬁnding that is in agreement with our hypoth-
esis that ﬂotillinsmay act as general key regulators of ErbB levels in sev-
eral cancer types.Hsp90 is known to bind and stabilize ErbB receptors [10,18,29].
Here, we demonstrate that the levels of all ErbB receptors are
dependent on Hsp90, with some variations in the dynamics of GA
induced degradation between the different breast cancer cell lines.
One might speculate that the cell lines exhibit varying kinds of
ErbB dimer combinations and that the effect of Hsp90 on receptor
stabilization differs depending on the speciﬁc dimer combination.
ErbB3 is dependent on Hsp90 in all the cell lines we tested, and we
know that ﬂotillins are interacting with Hsp90 in SKBR3 cells [33].
Therefore, it seems likely that Hsp90 acts as an important linker be-
tween ﬂotillins and ErbB receptors in breast cancer cells. Nevertheless,
Hsp90 is a chaperon and therefore might just have structural effects
on ErbB receptors and ﬂotillins. It has to be evaluated in future studies
whether Hsp90, ﬂotillins and ErbB3 are directly or indirectly interacting
with each other.
Fig. 5. Flotillin depletion results in reduced amount of ErbB2–ErbB3 complexes. ErbB2–ErbB3 proximity signals were measured by PLA and the number of dots per cell and per condition
weremeasured and normalized to control cells. ErbB2–ErbB3proximity signalswere signiﬁcantly decreased after 2 h of treatmentwith 3 μMGA, aswell as after knockdownofﬂotillin-1 or
ﬂotillin-2 in both SKBR3 (A, n = 3) and MCF7 cells (B, n = 4–5). (C) Immunoprecipitation of endogenous ErbB2 protein in SKBR3 cells resulted in a protein pulldown of co-
immunoprecipitated ErbB3 protein. Quantiﬁcation of four independent IP experiments shows a signiﬁcant reduction in the pulldown of ErbB2–ErbB3 complexes upon knockdown of
ﬂotillin-1 or ﬂotillin-2, as well as after 2 h treatment with 3 μM GA. Co-immunoprecipitated protein levels were normalized to the control. Mean + SD (* P b 0.05, ** P b 0.01,
*** P b 0.001). (D) Quantiﬁcation of co-immunoprecipitation experiments (n = 3–4) of endogenous ErbB2–ErbB3 protein complexes in SKBR3 cells upon ﬂotillin knockdown and/or
GA treatment (3 μM for 2 h). Immunoprecipitated proteins are normalized to the protein input levels that have been corrected for internal GAPDH loading. Data are presented as % of con-
trol condition. Antibodies used for immunoblotting and immunoprecipitation are speciﬁed in Materials and methods, Section 2.1.
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tion of ErbB2 and ErbB3 receptors in a variety of breast cancer cells.
Thus, ﬂotillins might function as general regulators of ErbB receptor ty-
rosine kinases in breast cancer and possibly other cancer types. The ac-
tivation of ErbB2–ErbB3 receptor complexes results in phosphorylation
of various effectors andmainly triggers theMAPK and the Akt pathways
[54,55]. Depletion of ﬂotillin-2 led to a signiﬁcant reduction in levels of
phosphorylated Akt andMAPK inMCF7 cells. However,ﬂotillin-1 deple-
tion did not affect p-AktSer473 and p-Erk1/2Thr202/Tyr204 levels. This selec-
tive effect upon ﬂotillin-2 depletion is consistent with our previously
reported data in SKBR3 cells [33]. Thus, only ﬂotillin-2 seems to have
an additional role in the regulation of Akt and MAPK signaling, but fur-
ther studies are required to conﬁrmwhether this is a general or cell type
speciﬁc phenotype. Upon depletion of ﬂotillin-2, we observe a slightly
stronger reduction of p-Akt levels (~40%) in SKBR3 cells [33] compared
toMCF7 cells (~30%). Flotillins are known to formhomo- and/or hetero-
oligomers [3,44]. Depletion of ﬂotillin-2 in SKBR3 cells induces substan-
tial degradation of ﬂotillin-1 [33], suggesting that ﬂotillin-1 stability de-
pends on the presence of ﬂotillin-2 in SKBR3but not inMCF7 cells. Thus,
cell type speciﬁc differences in the formation ofﬂotillin oligomersmight
explain the variations in the reduction of Akt phosphorylation in differ-
ent cell lines.
One of the main challenges in ErbB targeted cancer therapy is to in-
activate ErbB2–ErbB3 signaling complexes, as ErbB3 has been shown to
mediate compensatory mechanisms that allow cancer cells to restore
PI3K/Akt signaling and partially account for acquired resistance follow-
ing ErbB2 and/or ErbB1 targeted therapy [17,19,38].We showby immu-
noprecipitation and PLA that depletion of endogenous ﬂotillins leads toa selective reduction of ErbB2–ErbB3 complexes in SKBR3 and MCF7
cells. Quantitative analysis of our co-immunoprecipitation experiments
showed a 15–20% reduced association of ErbB2with ErbB3 uponﬂotillin
knockdown that is independent of reduced ErbB levels (Fig. 5D).
Thus, functional ﬂotillin proteins might speciﬁcally stabilize ErbB2–
ErbB3 receptor complexes in breast cancer cells and thereby preventing
receptor degradation and/or complex dissociation.
Beside a functional role in receptor stabilization, ﬂotillinsmight reg-
ulate ErbB receptors also by other mechanisms. Sorkina et al. recently
demonstrated that membrane mobility of the dopamine transporter is
regulated by ﬂotillins [45]. Furthermore, ﬂotillin-2 has been described
to regulate Rab11/SNX4-mediated sorting and recycling of transferrin
receptor and E-cadherin [42]. Thus, it will be important to analyze in de-
tail the speciﬁc function of ﬂotillins in ErbB receptor dimerization and
stabilization.
Flotillins are known to regulate key functions in cell migration [4,27]
and have been linked to metastasis in several cancer models [6,21,35].
Our data demonstrate that depletion of ﬂotillin-1 or ﬂotillin-2 leads to
a reduction in MCF7 breast cancer cell migration. ErbB2–ErbB3 hetero-
dimers have been shown to contribute to breast tumor metastasis
through enhancing tumor cell invasion in vivo [5,40,53]. Thus, ﬂotillin
depletion alone or in combination with its reduced ErbB levels and
ErbB2–ErbB3 complexes might be responsible for the effect on cell mi-
gration. However, no signiﬁcant change in cell velocity or directionality
after GA induced ErbB degradation was obtained in MCF7 cells. Since
Hsp90 is one of the most abundant proteins in the cytosol and acts on
diverse client proteins [46,50], we cannot exclude the possibility that
GA treatment might induce compensatory mechanisms or inhibit
Fig. 6. Flotillin depletion reduces Akt and Erk phosphorylation. (A) Representative West-
ern blots of p-AktSer473, Akt, p-Erk1/2Thr202/Tyr204 and Erk1/2 protein levels in ﬂotillin de-
pleted MCF7 cells. Quantiﬁcation of four independent experiments shows that depletion
of ﬂotillin-2 results in a signiﬁcant reduction in the levels of p-AktSer473 (B, black bars)
and p-Erk1/2Thr202/Tyr204 (C, black bars) with no change in the levels of total Akt (B, gray
bars) and Erk1/2 (C, gray bars). Flotillin-1 depletion did not affect Akt and Erk1/2 total
levels or phosphorylation (B and C, gray bars). Mean + SD (* P b 0.05). Antibodies used
for immunoblotting are speciﬁed in Materials and methods, Section 2.1.
Fig. 7. Reduced cell migration of MCF7 cells after ﬂotillin knockdown. Quantiﬁcation of
MCF7 cell directionality and velocity of control, GA-treated, ﬂotillin-1, ﬂotillin-2 or
ﬂotillin1+2 siRNA transfected cells in awound healing assay. Cell velocitywas signiﬁcant-
ly decreased in ﬂotillin-1,ﬂotillin-2 or ﬂotillin double knockdown cells compared to control
cells (black bars). A reduction in cell directionalitywas also observed inﬂotillin-2 or ﬂotillin
1+ 2 knockdown cells (gray bars). Mean + SD (* P b 0.05, ** P b 0.01, *** P b 0.001,
n = 3–5). Only non-dividing and vital single cells have been analyzed.
1995N. Asp et al. / Biochimica et Biophysica Acta 1843 (2014) 1987–1996proteins that are important for the regulation ofmigration processes. On
the other hand, increased cell migration upon ﬂotillin depletion has
been reported by Donatello et al. in MDA-MB-231 breast cancer cells
[15] and by Solis et al. in A431 carcinoma cells [43]. In contrast to
SKBR3 and MCF7 cells, MDA-MB-231 cells are ErbB2-negative and
A431 cells express high levels of EGFR. This might indicate that the
role of ﬂotillins in cell migration is cell type dependent aswell as depen-
dent on the expression level and dimerization status of ErbB receptors.
Therefore, it will be important to analyze in further experimentswheth-
er ﬂotillins also regulate invasion andmetastasis in breast cancer tissue
and other cancer types, and by which mechanisms these processes are
mediated.In summary, we demonstrate that knockdown of ﬂotillins induces
downregulation of ErbB2 and ErbB3 protein levels and in addition in-
duces a reduction of ErbB2–ErbB3 receptor complexes in different
human breast cancer cell lines. Given the importance of ErbB3 receptors
in human cancer progression, we provide evidence for a speciﬁc
ﬂotillin-mediated regulation of ErbB3 levels that can occur independent
of other ErbB receptors. Moreover, impaired cell migration is obtained
after ﬂotillin-1 or -2 knockdown but only depletion of ﬂotillin-2 results
in reduced levels of phosphorylated Akt and MAPK. Thus, ﬂotillins may
represent potent candidates for targeting ErbB2 and ErbB3 simulta-
neously and can be used to generate novel strategies for targeting
tumor growth and metastasis.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.bbamcr.2014.04.013.
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